These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 33527211)

  • 41. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Severe acute respiratory syndrome coronavirus-2 infection and the gut-liver axis.
    Mohandas S; Vairappan B
    J Dig Dis; 2020 Dec; 21(12):687-695. PubMed ID: 33099897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brain Renin-Angiotensin System: From Physiology to Pathology in Neuronal Complications Induced by SARS-CoV-2.
    Ahmadi S; Khaledi S
    Anal Cell Pathol (Amst); 2023; 2023():8883492. PubMed ID: 37575318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurological manifestations of coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19.
    Parsamanesh N; Pezeshgi A; Hemmati M; Jameshorani M; Saboory E
    Int J Neurosci; 2022 Sep; 132(9):917-924. PubMed ID: 33175635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
    Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
    J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection.
    Sun H; Su X; Huang L; Mu D; Qu Y
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33573324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review.
    Qu L; Chen C; Yin T; Fang Q; Hong Z; Zhou R; Tang H; Dong H
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19 extrapulmonary illness - special gastrointestinal and hepatic considerations.
    Perisetti A; Gajendran M; Mann R; Elhanafi S; Goyal H
    Dis Mon; 2020 Sep; 66(9):101064. PubMed ID: 32807535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
    Khoshkam Z; Aftabi Y; Stenvinkel P; Paige Lawrence B; Rezaei MH; Ichihara G; Fereidouni S
    J Adv Res; 2021 Jul; 31():49-60. PubMed ID: 33520309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.
    Li J; Wang Y; Liu Y; Zhang Z; Zhai Y; Dai Y; Wu Z; Nie X; Du L
    Eur J Med Res; 2022 Feb; 27(1):26. PubMed ID: 35193695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repressed Ang 1-7 in COVID-19 Is Inversely Associated with Inflammation and Coagulation.
    Carpenter RM; Young MK; Petri WAO; Lyons GR; Gilchrist C; Carey RM; Petri WA
    mSphere; 2022 Aug; 7(4):e0022022. PubMed ID: 35913134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of repurposed drugs for treating lung injury in COVID-19.
    He B; Garmire L
    F1000Res; 2020; 9():609. PubMed ID: 32934806
    [No Abstract]   [Full Text] [Related]  

  • 53. Implications of SARS-CoV-2 infection for neurogastroenterology.
    Marasco G; Lenti MV; Cremon C; Barbaro MR; Stanghellini V; Di Sabatino A; Barbara G
    Neurogastroenterol Motil; 2021 Mar; 33(3):e14104. PubMed ID: 33591607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.
    Loganathan S; Kuppusamy M; Wankhar W; Gurugubelli KR; Mahadevappa VH; Lepcha L; Choudhary AK
    Respir Physiol Neurobiol; 2021 Jan; 283():103548. PubMed ID: 32956843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Covid-19 and oral diseases: Crosstalk, synergy or association?
    Brandini DA; Takamiya AS; Thakkar P; Schaller S; Rahat R; Naqvi AR
    Rev Med Virol; 2021 Nov; 31(6):e2226. PubMed ID: 33646645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms.
    Du M; Yang S; Liu M; Liu J
    Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101793. PubMed ID: 34428501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. COVID-19, liver dysfunction and pathophysiology: A conceptual discussion.
    Gonçalves Júnior J
    World J Gastroenterol; 2022 Feb; 28(6):683-688. PubMed ID: 35317425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction.
    Amraei R; Rahimi N
    Cells; 2020 Jul; 9(7):. PubMed ID: 32660065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery; A review.
    Afrisham R; Jadidi Y; Davoudi M; Moayedi K; Karami S; Sadegh-Nejadi S; Ashtary-Larky D; Seyyedebrahimi S; Alizadeh S
    Epidemiol Infect; 2022 Sep; 150():e208. PubMed ID: 36128671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.